GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Innate Pharma SA (LTS:0EVI) » Definitions » Ending Cash Position

Innate Pharma (LTS:0EVI) Ending Cash Position : €69.99 Mil (As of Jun. 2024)


View and export this data going back to 2013. Start your Free Trial

What is Innate Pharma Ending Cash Position?

Innate Pharma's Ending Cash Position for the quarter that ended in Jun. 2024 was €69.99 Mil.

Innate Pharma's quarterly Ending Cash Position declined from Jun. 2023 (€71.41 Mil) to Dec. 2023 (€70.61 Mil) and declined from Dec. 2023 (€70.61 Mil) to Jun. 2024 (€69.99 Mil).

Innate Pharma's annual Ending Cash Position declined from Dec. 2021 (€103.76 Mil) to Dec. 2022 (€84.23 Mil) and declined from Dec. 2022 (€84.23 Mil) to Dec. 2023 (€70.61 Mil).

Innate Pharma Ending Cash Position Historical Data

The historical data trend for Innate Pharma's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Innate Pharma Ending Cash Position Chart

Innate Pharma Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Ending Cash Position
Get a 7-Day Free Trial Premium Member Only Premium Member Only 202.89 136.79 103.76 84.23 70.61

Innate Pharma Semi-Annual Data
Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
Ending Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 102.95 84.23 71.41 70.61 69.99

Innate Pharma Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

Innate Pharma's Ending Cash Position for the fiscal year that ended in Dec. 2023 is calculated as

Ending Cash Position= Beginning Cash Position+Net Change in Cash
=84.224+-13.619
=70.61

Innate Pharma's Ending Cash Position for the quarter that ended in Jun. 2024 is calculated as

Ending Cash Position=Beginning Cash Position+Net Change in Cash
=70.606+-0.616
=69.99

Innate Pharma Ending Cash Position Related Terms

Thank you for viewing the detailed overview of Innate Pharma's Ending Cash Position provided by GuruFocus.com. Please click on the following links to see related term pages.

Innate Pharma Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Innate Pharma SA (LTS:0EVI) » Definitions » Ending Cash Position
Comparable Companies
XPAR:ADOC XPAR:IVA XPAR:MAAT XPAR:TNG XPAR:NANO XPAR:ALCLS XPAR:ALSEN XPAR:OSE XPAR:DBV XPAR:GNFT VRTX ASX:CSL REGN XKRX:207940 XBRU:ARGX XBRU:UCB ALNY BNTX XKRX:068270 BGNE
Traded in Other Exchanges
IPHYF:USA IPHA:USA IPH:France IDD:Germany
Address
117, Avenue de Luminy, Marseille, FRA, 13009
Website
https://www.innate-pharma.com
Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. Its approach is to harness the innate immune system through therapeutic antibodies and its ANKET (Antibody-based NK cell Engager Therapeutics) proprietary platform. The company's revenue results from payments received to research, collaboration, and licensing agreements signed with pharmaceutical companies. Its product pipeline includes lacutamab, monalizumab, IPH5201, IPH5301, IPH6101, IPH62, IPH6401 and IPH6501.

Innate Pharma Headlines

No Headlines